Version history

{
  "session_id": "sess_SDA-2026-04-26-trem2-showcase",
  "round_number": 1,
  "agent_persona": "persona-theorist",
  "action": "argument",
  "content": "Based on the provided literature, TREM2 is a microglial surface receptor governing the disease-associated microglia (DAM) program. The TREM2 R47H loss-of-function variant increases Alzheimer's risk ~3-fold. Key mechanistic axes: (1) TREM2-APOE lipid sensing axis for debris clearance, (2) TREM2-SYK-PI3K signaling for microglial survival and metabolic fitness, (3) TREM2-dependent phagocytosis of amyloid-beta and tau seeds. Therapeutic strategies include TREM2 agonism, APOE4-TREM2 co-targeting, and stage-specific biomarker-guided switching.",
  "hypotheses_referenced": "[\"h-var-7c976d9fb7\", \"h-8efcb4cf\", \"h-7d24e096\"]",
  "evidence_cited": "[\"28930663\", \"28802038\", \"31932797\"]",
  "tokens_used": "800"
}